Clinical Trials Logo

Keratoconjunctivitis Sicca clinical trials

View clinical trials related to Keratoconjunctivitis Sicca.

Filter by:

NCT ID: NCT04938908 Completed - Dry Eye Syndrome Clinical Trials

Probiotic in Dry Eye Syndromes

Start date: July 1, 2021
Phase: Phase 2
Study type: Interventional

This study will evaluate efficacy and safety of systemic and ophthalmic probiotic from bacterial lysate of Lactobacillus sakei on microbiota, immunological and clinical outcomes of patients with Dry Eye Syndrome.

NCT ID: NCT04911361 Completed - Dry Eye Clinical Trials

The DEPOT Study (Dry Eye Prescription Options for Therapy)

Start date: August 10, 2021
Phase: Phase 4
Study type: Interventional

Assessing DEXTENZA efficacy and safety when placed within the lower eyelid canaliculus for dry eye flares in comparison to topical loteprednol suspension.

NCT ID: NCT04899518 Completed - Dry Eye Clinical Trials

ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

OASIS-1
Start date: May 19, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

Study Evaluating the Safety and Efficacy of Two Concentrations (0.4% and 1%) of ALY688 Ophthalmic Solution in Subjects with Dry Eye Disease

NCT ID: NCT04889950 Completed - Dry Eye Clinical Trials

Clinical Study to Evaluate the Safety and Effectiveness of The Tixel Fractional System in the Treatment of Meibomian Gland Disfunction

Start date: October 26, 2021
Phase: N/A
Study type: Interventional

A Randomized, Masked (Evaluator), Controlled, Prospective Pilot Study of the Effectiveness and Safety of the Tixel®, Versus LipiFlow® in the Treatment of Meibomian Gland Dysfunction. Up to 30 patients (60 eyes) to be randomized in up to 2 clinical sites in Israel and/or Europe. study subject will receive three (3) treatments with Tixel in a monthly interval, and a single treatment for the control group. Follow-up will occur 1 month and 3 months following the last treatment.

NCT ID: NCT04835623 Completed - Dry Eye Clinical Trials

CEQUA for Sjogren's Syndrome Dry Eye

Start date: June 21, 2021
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to show that CEQUA (cyclosporine 0.09% ophthalmic solution) improves symptoms of dry eye disease in a population of patients with Sjogren's Syndrome diagnosis.

NCT ID: NCT04831177 Completed - Clinical trials for Myopic LASIK Candidates With Spherical Equivalent up to - 10 Diopters

Thin-Flap Laser in Situ Keratomileusis Associated Dry Eye

Start date: June 1, 2019
Phase: N/A
Study type: Interventional

Laser in situ keratomileusis (LASIK) eye surgery continues to be the most common refractive procedure used to correct different forms of ametropia. Although the introduction of femtosecond technology has markedly reduced the incidence of intraoperative flap complications and allowed a better control on flap parameters, dry eye remains one of the most challenging postoperative complications.

NCT ID: NCT04830956 Completed - Dry Eye Clinical Trials

Evaluation of Comfort in Subjects With Moderate Dry Eye Disease

Start date: June 30, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the comfort of an ocular lubricant in dry eye subjects. This study will be conducted in Canada and Australia.

NCT ID: NCT04819269 Completed - Dry Eye Disease Clinical Trials

Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome

Start date: May 25, 2021
Phase: Phase 3
Study type: Interventional

This study will examine the efficacy and safety of tivanisiran sodium eye drops versus vehicle after a 2-week run-in phase when dosed once daily for 3 months in subjects with signs and symptoms of dry eye disease (DED) due to Sjögren's Syndrome.

NCT ID: NCT04762355 Completed - Dry Eye Disease Clinical Trials

Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Palovarotene Ophthalmic Solution in Healthy Adult Subjects

Start date: August 30, 2018
Phase: Phase 1
Study type: Interventional

Dry eye disease (DED) is a keratoconjunctive disorder that "is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. The goal of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of multiple ascending doses of palovarotene ophthalmic solution in healthy adult subjects.

NCT ID: NCT04747977 Completed - Dry Eye Clinical Trials

To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease

Start date: February 12, 2021
Phase: Phase 2
Study type: Interventional

To assess the efficacy and safety of OTX-DED for the short-term treatment of signs and symptoms of dry eye disease.